BTAI BioXcel Therapeutics Inc

Price (delayed)

$1.14

Market cap

$42.79M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.17

Enterprise value

$70.63M

BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. BioXcel's drug re-innovation approach leverages existing approved drugs and/or clinically ...

Highlights
BTAI's revenue is up by 27% since the previous quarter
BTAI's EPS is up by 22% year-on-year and by 16% since the previous quarter
BTAI's gross margin has surged by 177% since the previous quarter but it has dropped by 75% year-on-year
BTAI's quick ratio has dropped by 59% year-on-year
The equity has declined by 28% since the previous quarter

Key stats

What are the main financial stats of BTAI
Market
Shares outstanding
37.53M
Market cap
$42.79M
Enterprise value
$70.63M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
20.04
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
40.22
Earnings
Revenue
$1.76M
EBIT
-$139.5M
EBITDA
-$139.18M
Free cash flow
-$120.38M
Per share
EPS
-$5.17
Free cash flow per share
-$3.9
Book value per share
-$2.37
Revenue per share
$0.06
TBVPS
$2.67
Balance sheet
Total assets
$82.32M
Total liabilities
$154.69M
Debt
$101.98M
Equity
-$72.36M
Working capital
$49.44M
Liquidity
Debt to equity
-1.41
Current ratio
2.57
Quick ratio
2.37
Net debt/EBITDA
-0.2
Margins
EBITDA margin
-7,925.9%
Gross margin
24.1%
Net margin
-8,715.7%
Operating margin
-8,243.1%
Efficiency
Return on assets
-154.4%
Return on equity
N/A
Return on invested capital
-181.8%
Return on capital employed
-274.4%
Return on sales
-7,943.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BTAI stock price

How has the BioXcel Therapeutics stock price performed over time
Intraday
0%
1 week
-16.79%
1 month
-43.28%
1 year
-94.02%
YTD
-61.36%
QTD
-59.57%

Financial performance

How have BioXcel Therapeutics's revenue and profit performed over time
Revenue
$1.76M
Gross profit
$424,000
Operating income
-$144.75M
Net income
-$153.05M
Gross margin
24.1%
Net margin
-8,715.7%
BTAI's gross margin has surged by 177% since the previous quarter but it has dropped by 75% year-on-year
BTAI's operating margin has soared by 73% YoY and by 34% QoQ
BTAI's net margin has surged by 73% year-on-year and by 33% since the previous quarter
BTAI's revenue is up by 27% since the previous quarter

Growth

What is BioXcel Therapeutics's growth rate over time

Valuation

What is BioXcel Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
20.04
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
40.22
BTAI's EPS is up by 22% year-on-year and by 16% since the previous quarter
The equity has declined by 28% since the previous quarter
The price to sales (P/S) is 78% lower than the last 4 quarters average of 89.7
BTAI's revenue is up by 27% since the previous quarter

Efficiency

How efficient is BioXcel Therapeutics business performance
BioXcel Therapeutics's return on assets has shrunk by 81% YoY and by 7% QoQ
BTAI's return on sales has surged by 74% year-on-year and by 34% since the previous quarter
BioXcel Therapeutics's ROIC has increased by 24% YoY and by 15% from the previous quarter

Dividends

What is BTAI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BTAI.

Financial health

How did BioXcel Therapeutics financials performed over time
The total assets is 47% less than the total liabilities
BTAI's quick ratio has dropped by 59% year-on-year
BTAI's current ratio has plunged by 58% YoY and by 3% from the previous quarter
BioXcel Therapeutics's debt to equity has plunged by 178% YoY but it has increased by 21% from the previous quarter
The equity has declined by 28% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.